RxDoctor Payments Data

James Bleiler, MD

Urology · Falmouth, MANPI 1679539506

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,723 of the $12,150 with a category attached, or 80.0%. It is spread thinly across 58 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations.

$12,150in general payments, 2019–2025

Across 465 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$2K
  • Neotract Inc.$1K
  • Astellas Pharma US Inc$1K
  • Johnson & Johnson$1K
  • Sumitomo Pharma America, Inc.$715
  • Pfizer$632
  • plus $5K from 52 others

What the payments were for

  • Travel & lodging$1,90416%
  • Food & beverage$9,72380%
  • Education$5224%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,150 in reported general payments places this provider in the 85th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$1,435,902
Medicare patients
2,060
Services billed
65,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide48$561,632
ErleadaApalutamide18$264,991
Thiola EcTiopronin12$121,327
GemtesaVibegron122$117,797
OrgovyxRelugolix34$92,493
MyrbetriqMirabegron74$71,442
Abiraterone Acetate25$43,792
Tamsulosin Hcl975$17,218
Methenamine Hippurate126$8,691
Finasteride575$8,513
Alfuzosin Hcl ErAlfuzosin Hcl181$3,871
Estradiol27$2,555
Testosterone24$2,049
Oxybutynin Chloride103$1,798
Cephalexin137$1,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,101$633,074122 claims
Johnson & JohnsonErleada$1,051$264,99118 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$715$210,290156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 327 urology providers in Massachusetts.

Other urology in Falmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →